达芦那韦药物全球专利布局与研发态势分析
|
郑丽丽,赵亚娟,吕璐成,赵萍,魏雪梅
|
Analysis of Patents Related to Clinical Trial Drugs of COVID-19 -Darunavir
|
Lili Zheng,Yajuan Zhao,Lucheng Lyu,Ping Zhao,Xuemei Wei
|
|
表1 杨森科学公司达芦那韦相关专利国家/地区布局趋势 |
|
|
年度 | 中国 | 美国 | 韩国 | 欧洲 | 日本 | 中国台湾 | 德国 | WO | 澳大利亚 | 加拿大 | 2007 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 2008 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 2009 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2010 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2011 | 29 | 29 | 29 | 29 | 29 | 0 | 0 | 29 | 29 | 29 | 2012 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2013 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2014 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2015 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2016 | 7 | 7 | 7 | 7 | 7 | 0 | 0 | 7 | 7 | 7 | 2017 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 2018 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 合计 | 38 | 40 | 36 | 38 | 38 | 1 | 0 | 40 | 39 | 38 |
|
|
|